Pilot experience in the treatment of poor-prognosis primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with a modified program NHL-BFM-90

• Main Authors: Anna Konstantinovna Morozova, Evgeniy Evgen'evich Zvonkov, Aleksandra Mikhaylovna Kremenetskaya, Aminat Umuraskhabovna Magomedova, Tat'yana Nikiforovna Obukhova, Vasiliy Evgen'evich Mamonov, Elena Aleksandrovna Baryakh, Andrey Vladimirovich Gubkin, Aleksandra Ivanovna Lukina, Ekaterina Alekseevna Ilyushkina, Olesya Sergeevna Fink, Tat'yana Nikolaevna Perestoronina, Sergey Kirillovich Kravchenko, A K Morosova, E E Zvonkov, A M Kremenetskaya, A U Magomedova, T N Obukhova, V E Mamonov, E A Baryakh, A V Gubkin, A I Lukina, E A Ilyushkina, O S Fink, T N Perestoronina, S K Kravchenko
• Format: Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 2009-07-01
• Series: Терапевтический архив
• Subjects: diffuse large b-cell lymphosarcoma; bones; soft tissues; high-dose polychemotherapy
• Online Access: https://ter-arkhiv.ru/0040-3660/article/view/30405

Aim. To evaluate efficacy of intensive modified program NHL-BFM-90 (mNHL-BFM-90) in adult poor-prognosis patients with diffuse large B-cell lymphosarcoma (DLBCL) of the bones and soft tissues. Material and methods. The mNHL-BFM-90 program was used in the treatment of 3 male and 2 female patients aged 17-69 years (median 42 years). Four patients had DLBCL of the bones and one patient - DLBCL of the soft tissues. All the patients had tumors more than 10 cm in size. B-symptoms, a high concentration of lactate dehydrogenase (LDG) were registered in 3 patients. One patient had stage IE by Ann-Arbor, two - stage IIE (involvement of regional lymph nodes), two - stage ME (multiple bone lesions). A total of 4-6 blocks of polychemotherapy according to mNHL-BFM-90 program were performed. Results. Complete remissions were achieved in all the patients. They had no recurrences after 6 to 20 month (median 13 months) follow-up. Conclusion. Positive results of the program mNHL-BFM-90 in poor-prognosis patients with DLBCL of the bones and tissues necessitate further studies of this therapy.